drugset / Trial / NCT05411484

Investigation of Laser Assisted Drug Delivery of NanoDOX®

NCT05411484

Phase 2 Active not recruiting 10 enrolled Massachusetts General Hospital NanoSHIFT LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a self-controlled single-site study of healthy subjects receiving an ablative fractional CO2 (carbon dioxide) laser procedure followed by topical application of NanoDOX® Hydrogel (1% doxycycline). The study includes skin biopsies to evaluate the effects of NanoDOX® Doxycycline Monohydrate Gel on wound healing after the ablative laser procedure. Study subjects will be asked to do 2 visits of 4 hours in total over approximately 1 week. An optional third visit will take place approximately 6 weeks after Visit 1. In this study, 20 subjects are expected to enroll with a goal of 12 healthy subjects to enroll and complete the study.

Timeline

Start
2023-11-29
Primary completion
2027-03
Completion
2027-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 1 % Topical

Indications

No indication recorded.